Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

EBV vaccine could prevent mononucleosis and cancers linked to virus

In a new article from the National Institutes of Health (NIH), Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), and Harold Varmus, M.D., director of the National Cancer Institute (NCI), join Gary Nabel, M.D., Ph.D., director of NIAID's Vaccine Research Center, and Jeffrey Cohen, M.D., chief of NIAID's Laboratory of Infectious Diseases, in summarizing a recent meeting of experts who gathered to map directions toward an EBV vaccine.

3 Nov 2011

Dramatic rise in U.S. incidence of oropharyngeal cancer can be attributed to HPV infection

A new study of oropharyngeal cancer suggests that dramatic increases in U.S. incidence of the cancer and survival since 1984 can be attributed to infection with the human papillomavirus.

4 Oct 2011

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Research in Switzerland could help reduce the time taken to develop vaccines against cancer tumours.

27 Sep 2011

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that it has completed enrollment in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

12 Sep 2011

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Bristol-Myers Squibb Company today announced that new data on NULOJIX (belatacept) will be presented at the European Society for Organ Transplantation (ESOT) Congress on September 4 -7, 2011 in Glasgow, Scotland, United Kingdom.

2 Sep 2011

Tiny molecule could bind to B cell EB12 receptor and prevent cancer

Infection with Epstein Barr means that the B cells, which are the primary memory cells of the immune system, are hi-jacked. When the virus has penetrated, researchers observe an excess of a special bio-antenna, a receptor known as EB12, suddenly sprouting from the surface of the B cells. But why they do so remains a mystery.

22 Aug 2011

DNA vaccine developer Coridon in U.S. collaboration

DNA vaccine development company Coridon Pty Ltd. today announced that it has entered into a research collaboration agreement with The Ohio State University to progress its Epstein Barr Virus (EBV) project.

19 Jul 2011

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced that patient dosing has begun in the AdV HALT Trial (A Randomized, Placebo-Controlled, Multi-site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation [HSCT]).

14 Jul 2011

Promising results from MGH's BCG Phase I trial on type I diabetes

Promising results of the Phase I clinical trial of the generic drug BCG to treat advanced type I diabetes were announced today at the American Diabetes Association scientific sessions in San Diego.

27 Jun 2011

FDA approves NULOJIX

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) approved NULOJIX, the first selective T-cell costimulation blocker indicated for the prophylaxis of organ rejection in adult patients receiving a kidney transplant, in combination with basiliximab induction, mycophenolate mofetil (MMF), and corticosteroids.

18 Jun 2011

Bristol-Myers Squibb receives FDA approval for Nulojix to prevent organ rejection after kidney transplant

The U.S. Food and Drug Administration today approved Nulojix to prevent acute rejection in adult patients who have had a kidney transplant. The drug is approved for use with other immunosuppressants -- specifically basiliximab, mycophenolate mofetil, and corticosteroids.

16 Jun 2011

Epstein-Barr virus might cause multiple sclerosis, study confirms

The Epstein-Barr (EVB) virus -belonging to the herpesviruses family, which also includes the herpes simplex virus and the cytomegalovirus- is one of the environmental factors that might cause multiple sclerosis, a condition affecting the central nervous system, which causes are unknown.

18 May 2011

Pediatric researchers find potential tools for controlling cytokine storm

By analyzing complex interactions of the immune system in an animal study, pediatric researchers have found potential tools for controlling a life-threatening condition called a cytokine storm that may strike children who have juvenile arthritis and other autoimmune diseases.

17 May 2011

HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease

HemaQuest Pharmaceuticals, Inc., a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, announced today that clinical investigators have enrolled the first patient in a randomized multi-dose Phase 2 study of HQK-1001 in patients with sickle cell disease.

26 Apr 2011

The Healthy Home book on reducing health hazards advances in ranking on best sellers lists

The Healthy Home, a new book providing simple solutions for reducing toxins and other health hazards in the home, has advanced in ranking on several national best sellers lists within a month of publication. After becoming a Top 100 Amazon.com best seller following its first week of sales, The Healthy Home, released on March 22, quickly hit the New York Times, USA TODAY, Publishers Weekly and L.A. Times best sellers lists.

22 Apr 2011

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

By identifying a surprising association of two intracellular proteins, University of Iowa researchers have laid the groundwork for the development of new therapies to treat B cell lymphomas and autoimmune disease.

20 Apr 2011

People with infectious mononucleosis, low UVB exposure may face high risk of MS

New research suggests that people who are exposed to low levels of sunlight coupled with a history of having a common virus known as mononucleosis may be at greater odds of developing multiple sclerosis than those without the virus.

19 Apr 2011

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

Abbott (NYSE: ABT) announced today that it has received CE-Mark for a new qualitative PCR-based HIV-1 test that produces highly accurate results from dried blood spot and plasma specimens. The new assay is a long-awaited diagnostic tool for health officials in African nations and other resource-limited areas to detect HIV-1 infected infants at early stages and begin treatment when success is more likely.

21 Mar 2011

New research may shed light on how HIV virus reactivates from latency

New research enhances the current knowledge of how human immunodeficiency virus type-1, which causes AIDS, controls the cell cycle of cells that it infects. The new findings may shed light on how the virus reactivates after entering a dormant state, called latency.

28 Feb 2011

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

EBV vaccine could prevent mononucleosis and cancers linked to virus

Dramatic rise in U.S. incidence of oropharyngeal cancer can be attributed to HPV infection

University of Zurich receives AICR grant to improve vaccines against Burkitt's lymphoma

Enrollment complete in HemaQuest HQK-1001 Phase 2 study in sickle cell disease

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Tiny molecule could bind to B cell EB12 receptor and prevent cancer

DNA vaccine developer Coridon in U.S. collaboration

Chimerix initiates CMX001 Phase 2 study for prevention of adenovirus disease following HSCT

Promising results from MGH's BCG Phase I trial on type I diabetes

FDA approves NULOJIX

Bristol-Myers Squibb receives FDA approval for Nulojix to prevent organ rejection after kidney transplant

Epstein-Barr virus might cause multiple sclerosis, study confirms

Pediatric researchers find potential tools for controlling cytokine storm

HemaQuest initiates HQK-1001 Phase 2 study in sickle cell disease

The Healthy Home book on reducing health hazards advances in ranking on best sellers lists

LMP1 viral protein needs TRAF6 cellular protein to promote B cell activation signaling pathways: Study

People with infectious mononucleosis, low UVB exposure may face high risk of MS

Abbott receives CE-Mark for new qualitative PCR-based HIV-1 test

New research may shed light on how HIV virus reactivates from latency

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Epstein Barr Virus News and Research

Latest Epstein Barr Virus News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in